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Abstract Quantitative information from magnetic reso-
nance imaging (MRI) may substantiate clinical findings and
provide additional insight into the mechanism of clinical
interventions in therapeutic stroke trials. The PERFORM
study is exploring the efficacy of terutroban versus aspirin
for secondary prevention in patients with a history of
ischemic stroke. We report on the design of an exploratory
longitudinal MRI follow-up study that was performed in a
subgroup of the PERFORM trial. An international multi-
centre longitudinal follow-up MRI study was designed for
different MR systems employing safety and efficacy read-
outs: new T2 lesions, new DWI lesions, whole brain volume
change, hippocampal volume change, changes in tissue
microstructure as depicted by mean diffusivity and
fractional anisotropy, vessel patency on MR angiography,
and the presence of and development of new microbleeds. A
total of 1,056 patients (men and women C55 years) were
included. The data analysis included 3D reformation, image
registration of different contrasts, tissue segmentation, and
automated lesion detection. This large international multi-
centre study demonstrates how new MRI readouts can be
used to provide key information on the evolution of cerebral
tissue lesions and within the macrovasculature after ather-
othrombotic stroke in a large sample of patients.
Keywords MRI  Lesion load  Brain atrophy 
Microbleeds  PERFORM  Longitudinal brain disease
progression
Introduction
During the last 20 years, novel magnetic resonance imaging
(MRI) techniques have emerged that allow the non-invasive
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and rapid assessment of brain functioning and cerebral tissue
lesions [1]. The MRI is now utilized as the primary imaging
modality in major stroke centres to detect and measure
cerebral tissue lesions as well as changes in the vascular
structure [2]. Moreover, it becomes an accepted feature of
clinical trials in a variety of neurological disorders, and
particularly in stroke. New MRI markers of cerebrovascular
diseases (microbleeds, diffusion) have been recently evalu-
ated offering reliable parameters of assessment of clinical
outcome [3, 4]. There are few longitudinal neuro-radiolog-
ical data assessed in large stroke trials, which mostly are
based on the clinical evaluation. In this context the PER-
FORM (Prevention of Cerebrovascular and Cardiovascular
Events of Ischemic Origin with Terutroban in Patients with a
History of Ischemic Stroke or Transient Ischemic Attack)
MRI project was designed to depict by MRI structural and
functional information on the evolution of cerebral athero-
thrombotic processes after a recent ischemic stroke. The aim
of this major sub study is to provide a longitudinal assess-
ment of multiple MRI parameters in a large subgroup of a
post stroke population with a follow-up of 2 years. The
rationale and design of the PERFORM study, which includes
19,119 patients randomly allocated either to terutroban, a
specific thromboxane prostaglandin (TP) receptor antagonist
[5], 30 mg/day, or to aspirin 100 mg/day, have been
described elsewhere, together with the characteristics of the
whole population at baseline [6, 7]. Herein we report the
design, framework and conduct for this complex interna-
tional multi-centre longitudinal study. In particular, the MRI
methodology chosen and the data that can be obtained in such
a large MRI study are presented.
Design
Subjects
The patients included in the study were aged C55 years, had
a cerebral or retinal infarction in the last 3 months preceding
inclusion or TIA in the last 8 days, and were stable at
inclusion. They did not have any MRI contraindication such
as known risk for exposure to high magnetic fields (e.g.,
pacemakers, implanted ferromagnetic devices, metallic
implants, metal fragments, cochlear implants, brain and
spinal cord stimulators), severe claustrophobia and difficulty
lying in supine position. MRI quality check performed at M1
was validated by the imaging core lab of BioClinica.
Study scheme
The trial profile of the PERFORM MRI project is shown in
Fig. 1. Two MRIs were planned to be performed in each
patient included in the study: the first at month 1 (M1),
1–4 months after the qualifying clinical event and the
second at month 24 (M24).
Participants were fully informed and written consent
was obtained according to local regulatory requirements.
MRI acquisition
Before the initiation of the study, a total of 48 MRI sites
from 16 countries (11 from Europe, and one each from
Australia, Canada, Brazil, Singapore and Taiwan) were
selected. MRI scans were performed on 1.5 Tesla scanners
in 42 sites and on 3T scanners in six sites.
The MRI protocol was implemented at each site fol-
lowing imaging parameter suggestions to ensure stan-
dardization across sites and different MRI systems, and to
maximize consistency and comparability between data
from different manufacturers. Numbers, vendors, models
and field strengths of all MRI machines used are listed in
Table 1. Each site was qualified using ACR phantom scans
[8], to monitor image quality, in particular for geometrical
distortions and adherence to the study protocol. The
phantom scans were to be repeated yearly and after each
significant software and hardware upgrade. Ten machines
had a major hardware upgrade including system change in
six cases, but due to phantom validation we could mini-
mize as much as possible the effect of such changes that
affected a relatively small number of patients. All scans
included transverse fluid attenuated inversion recovery
(FLAIR), gradient-echo T2*-weighted (T2*-weighted),
diffusion weighted imaging (DWI) (three directions), 3D
time-of-flight (TOF) MR angiography and high-resolution
sagittal 3DT1 sequences. For sites with diffusion tensor
imaging, transverse DTI (six directions) data were also
performed. The total acquisition time was kept reasonably
low (from 30 to 45 min, according to the MRI system) to
minimize patient’s discomfort. Two-dimensional sequen-
ces were made of 5-mm thick contiguous slices with a
240 mm FOV and at least a 192 9 256 matrix (128 9 128







Fig. 1 The trial profile of the PERFORM MRI project
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for DWI and DTI). TOF-MRA sequence was made of
1.6-mm thick slices with a 200 mm FOV and at least a
256 9 256 matrix. The 3DT1 protocol was chosen to fol-
low ADNI recommendations [9] (1.2-mm thick slices,
240 mm FOV, 192 9 192 matrix), with slight modifica-
tions to reduce scan time.
Image management and reading sessions
All scans were centralized by BioClinica and quality was
controlled to check for protocol compliance and image
quality. In case of significant quality issues, repeat scans
were requested. A MRI examination of insufficient quality
at M1 excluded the patient from the study. For follow-up
timepoints, only image data of sufficient quality were
planned to be used for analysis.
After centralization and quality control and before
submission to the readers, the image data were processed
by the core lab. The aim of the image processing was to
prepare the image data for centralized evaluation and to
pre-detect the different structures of interest (such as white
matter lesions, brain parenchyma, hippocampus) to
improve the efficiency and the quality of centralized
evaluations. This included various post-processing algo-
rithms, e.g., 3D reformation, image registration, tissue
segmentation, automated lesion detection to ensure best
possible comparability. After these preparatory steps,
image evaluations were carried out under supervision of
BioClinica at remote sites on dedicated workstations by
independent neuro-radiologists unaware of clinical infor-
mation using a standardized procedure.
MRI assessment
Focal tissue changes related to the vascular pathology were
to be assessed from M1 and M24 on FLAIR (new inci-
dental infarcts and other white matter changes and changes
of lesion volume), T2* (microbleeds identified as hypoin-
tense lesions) and DWI (incidental acute infarcts at M24).
Changes in brain volume occurring between M1 and M24
to assess global brain atrophy and hippocampal were
planned to be evaluated on the 3DT1 data set. Brain
microstructural tissue changes were to be assessed from
M1 and M24 on diffusion tensor imaging (DTI) using
apparent diffusion coefficient (ADC) and fractional
anisotropy (FA) maps.
Lesion load
Lesion load assessment on FLAIR sequences has been
selected as FLAIR was previously recognized as more
sensitive and specific than conventional or fast spin echo
T2-weighted magnetic resonance imaging (MRI) for
detecting lesions in the brain of patients with ischemic
brain disease [10]. Its major advantages over T2 are a
better sensitivity for small infarctions close to the sulci and
a better differentiation between Virchow–Robin spaces, old
lacunes and other white matter lesions [11]. Diffusion
weighted imaging (DWI) was chosen as known to be very
sensitive to detect acute ischemic stroke events [12].
Hyperintense FLAIR lesions, hypointense FLAIR
lesions and hyperintense DWI lesions were pre-detected
using an unsupervised 3D segmentation algorithm on
FLAIR and DWI isotropic images after skull removal, and
manually validated prior to submission to the readers
(Fig. 2).
Brain and hippocampal atrophy
Brain parenchyma was pre-detected using a 3D segmen-
tation algorithm on 3DT1 images after removal of the skull
by 3D deformable registration of a brain atlas, and manu-
ally validated prior to submission to the readers (Fig. 3).
Left and right brain volumes were derived from the total
brain volume results using the interhemispheric plane as
detected at M1 on sagittal 3DT1 images. These surrogate
measurements allowed us to measure the impact of brain
Table 1 Numbers, vendors, models and field strengths of all MRI
machines used
Number Vendor Model Field
17 GE Signa Excite 1.5
2 GE Signa Excite 3
7 GE Signa HDx 1.5
5 GE Signa HDxt 1.5
5 GE Signa Horizon 1.5
1 GE Signa Infinity 1.5
5 Philips Achieva 1.5
1 Philips Achieva 3
9 Philips Intera 1.5
4 Philips Intera 3
1 Philips Intera Achieva 1.5
5 Philips Intera Achieva 3
1 Philips Gyroscan Intera 1.5
12 Siemens Avanto 1.5
6 Siemens Sonata 1.5
8 Siemens Symphony 1.5
7 Siemens Symphony Tim 1.5
1 Siemens Symphony Vision 1.5
3 Siemens Trio Tim 3
1 Siemens Vision Plus 1.5
1 Picker/Marconi Edge Eclipse 1.5
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atrophy with more accuracy on the contra-lateral hemi-
sphere, as the initial infarct and surrounding tissue changes
did not affect this measurement.
The Jacobian integration, a quantitative technique based
on a 3D non-rigid matching of baseline and follow-up MRI
examinations [13] was used for the assessment of the
longitudinal brain volume changes. As a registration-based
technique, it requires less manual interactions with respect
to a segmentation-based technique or the boundary shift
integral [14, 15] and allows the detection of small brain
volume changes [16].
The hippocampal volume was defined as the complex
interfolded layers of the cornu ammonis (grey matter), the
dentate gyrus (grey matter), the alveus (white matter), the
subiculum (grey matter) and the fimbria (white matter).
The hippocampal–amygdalar boundary was identified
with reference to the temporal horn of the ventricles and,
where possible, to the presence of the alveus. Hippocampal
Fig. 2 Lesion detection. From
left to right, hyperintense
FLAIR lesions, hypointense
FLAIR lesions, and
hyperintense DWI lesions were
pre-detected using an
unsupervised 3D segmentation
algorithm after skull removal,
and manually validated prior to
submission to readers
Fig. 3 Brain parenchyma
detection. Brain parenchyma
contours (in red) was pre-
detected using a 3D
segmentation algorithm on
3DT1 images by 3D deformable
registration of a brain atlas, after
skull removal, and manually
validated prior to submission to
the readers. Interhemispheric
plane is shown in yellow
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contours were pre-detected using a semi-automatic tech-
nique prior to submission to the readers for confirmation
(Fig. 4).
For both brain parenchyma and hippocampal masks,
3DT1 data were displayed in a multiplanar reformatted
mode so that the readers were able to use the sagittal
(native), coronal and transverse orientations when cor-
recting the pre-detected masks.
The volume of the intracranial cavity was used to nor-
malize the different volumetric measurements. The T2*
sequence was used for this purpose as it clearly depicts
external CSF. Given that the full brain coverage could not
be achieved for all patients (24–28 slices of 5 mm were
used), the 3DT1 sequence was automatically coregistered
to T2* and used to manually complete for potentially
missing upper and lower slices, and correct for T2*-related
artifacts (Fig. 5).
Microbleeds
Cerebral microbleeds [17, 18] were defined as punctuate,
homogeneous, rounded, hypointense lesions smaller than
5 mm in size, visualised on T2* sequences. They were
counted throughout the brain by the readers (Fig. 6).
Hypointense lesions in the subarachnoid space were con-
sidered likely to represent adjacent pial blood vessels and,
therefore, were not included in the analysis. Symmetrical
hypointensities in the globi pallidi (likely to represent
calcifications or iron deposition) and flow voids from
cortical vessels were also disregarded.
Cerebral microbleeds were also categorized using the
following classification: cortical or cortico-subcortical and
juxtacortical (\5 mm from cortex) on one hand, or deep
and infratentorial (including brainstem, cerebellum, thala-
mus, etc.) on the other hand.
Brain microstructural tissue changes
Diffusion tensor imaging (DTI) is a magnetic reso-
nance imaging technique that measures the directionally
dependent rate of water self-diffusion in each image
voxel.
Subcortical white matter ischemic injury causes reduc-
tions in the oriented organization of white matter pathways
Fig. 4 Hippocampus detection.
Hippocampal contours (in red)
were pre-detected using a semi-
automatic technique prior to
submission to the readers for
confirmation
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partly due to demyelination and fiber loss with a corre-
sponding reduction in anisotropy [19].
DTI is sensitive to these changes in anisotropy, making
it a powerful in vivo imaging tool for studying the
microstructural integrity of cerebral white matter [20].
The apparent diffusion coefficient (ADC) which mea-
sures the rate of diffusion in each image voxel, and frac-
tional anisotropy (FA), a measure of the extent to which the
diffusion is directionally restricted are used as their scalar
values seem to be more robust and suited to group com-
parisons [21]. For DWI and DTI sequences, the peak,
mean, standard deviation and height values were extracted
from histogram data. Each DWI and DTI sequence were
independently processed by the core lab to suppress the
extrameningeal structures and to suppress the CSF voxels
in order to restrict the histogram analysis only to the brain
parenchyma, and to generate the ADC and FA maps.
Normalized histograms were then computed over the
whole brain and over the normal appearing brain tissue (as




The primary efficacy criteria of the study were lesion
changes and brain volume changes between M1 and M24.
All these parameters were assessed globally but also with
regard to the side of the lesion of the initial ischemic event.
The identification of the ipsilateral and contralateral
hemispheres allows us to evaluate, in addition to the gen-
eral progression of the cerebrovascular disease, the specific
evolution of the disease in relation to the initial event.
As a criterion of interest for safety the number of
emergent microbleeds was identified.
Statistical analysis
The PERFORM MRI project analyses will be under the
supervision of the Biometry Division of the Institut de
Recherches Internationales Servier. The analyses will be
performed in all patients having taken the study drug and




smaller than 5 mm in size,
visualised on T2* sequences, (in
red), were counted throughout
the brain by the readers, and
classified as cortical, cortico-
subcortical, juxtacortical or
deep and infratentorial
Fig. 5 Intracranial cavity
detection. The T2* sequence
was used to detect the
intracranial cavity contours (in
red) as it clearly depicts external
CSF (left). Given the lack of full
brain coverage for all patients
the 3DT1 sequence was
automatically coregistered to
T2*, resliced in the axial plane,
and used to manually complete
for potentially missing upper
and lower slices (right)
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having M1 and M24 MRI examinations. Efficacy criteria
will be analyzed in raw data as well as normalized data
(normalization by the intracranial cavity volume) and will
be expressed in change or relative change. Covariance
analysis models adjusted for M1 value will be used to
estimate the treatment effect, its 95% CI and associated
p value.
The number of emergent microbleeds will be counted by
treatment group and a 95% CI of the treatment effect will
be provided.
Inter- and intra-reader variability
Although all readers were highly qualified clinical stroke
MRI readers, multiple readers were assigned to the same
read tasks to ensure general consistency. In order to
ensure the quality of evaluation results throughout the
study and among the readers, the inter- and intra-reader
reproducibility was monitored based on double reads of
5% of all evaluations. The criteria for acceptable intra-
and inter-variability rates were related to each type of
MRI reading task. A threshold was chosen initially for
each task and when the differences between two readers
were higher than this threshold the readers were asked to
repeat their reads after taking consensual decisions in
order to improve reproducibility. When the variability
was larger than expected, the concerned case was sys-
tematically reviewed and a consensual decision was
made.
The following criteria for acceptable intra- and inter-
rater variability rates between two double-readings were
related to the MRI parameters. For global brain volumes a
relative threshold of 1% of variability was accepted. For
hippocampal volumes or for intracranial cavity volume, 5%
of variability was accepted. For lesion volumes both a
relative and an absolute thresholds were used: 5% of var-
iability or an absolute volume variation of less than
300 mm3 was chosen for hyperintense FLAIR lesions, 3%
or 100 mm3 for hypointense FLAIR lesions, and 3% or
300 mm3 for hyperintense DWI lesions. Regarding mi-
crobleeds, these were categorized in four classes (0 bleeds,
12 bleeds, 3–10 bleeds, [10 bleeds) and two double-
readings were found as discrepant if their results led to
classification in a different class.
Population baseline characteristics
Recruitment into the PERFORM MRI project started on
February 22, 2006 and the last patient was randomized on
February 25, 2008. A total of 1,056 patients were ran-
domized from 48 MRI centers in 16 countries; 53% of the
population was recruited in western Europe, 13% in
Australia, 12% in Asia, 11% in Brazil, 8% in eastern
Europe and 3% in Canada.
Demographic characteristics and past medical history
are presented in Table 2. The mean age of the population
was 67.7 ± 8 years (range 55–98 years), with 22% of
patients over 75 years. Sixty-five percent of the population
was male and 81% of Caucasian origin. The most frequent
risk factors were hypertension (84%), hypercholesterol-
emia (50%), and diabetes (30%). Eleven percent (11%) of
the population reported a previous ischemic stroke and 7%
a previous TIA, while 7% had a history of myocardial
infarction.
At baseline, after the qualifying stroke, 76% of the
patients were receiving medical treatment with a statin, and
57% with an angiotensin-converting enzyme inhibitor.
Data relative to the qualifying event and disease char-
acteristics are presented in Table 3.
Eighty-seven percent of the qualifying events were
ischemic stroke. According to the pre-specified ischemic
stroke classification, atherothrombotic or likely athero-
thrombotic stroke represents 69% of the ischemic stroke
population and 26% had a lacunar stroke.




Mean age, years 68
Age, %
\65 years 39










Type II diabetes mellitus 30
Prior history of cerebral infarction 11
Angina pectoris 6
Hypertriglyceridemia 6
Prior history of TIA 7
Myocardial infarction 7
Peripheral artery disease 3
Previous treatmentsa, %
Statins 76
Angiotensin-converting enzyme inhibitors 57
a Recorded between index stroke and randomization
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According to the Modified Rankin Scale scores at
baseline, 87% of the patients had scores B2, indicative of
no or slight disability.
These data were comparable to the main study popula-
tion characteristics [7].
Conclusion
The PERFORM MRI study is an exemplary study of a
large-scale international multi-centre trial. Although such
studies are expected, the complexity and difficulties at
various levels have been hindering factors in the past. We
describe the rationale, design and practical organization of
a large stroke patient MRI trial. The project should provide
important data on longitudinal brain disease progression
with a follow-up of 2 years.
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Appendix
Principal investigators from MRI centres per country
Australia: C. Bladin, S. Davis, R. Helme, C. Levi,
R. Schwartz; Austria: R. Schmidt, M. Vosko, J. Willeit;
Belgium: P. Desfontaines, A. Michotte; Brazil: M. T. T. Da
Silva, A. C. A. Ferraz, M. S. G. Rocha, J. R. C. B. Silveira;
Canada: M. Hill, F. Silver, P. Teal; France: P. Clavelou,
I. Crassard, T. De Broucker, C. Lamy, T. Moulin, C. Robin;
Germany: J. Berrouschot, A. Grau, G. Hamann, L. Harms,
R. Stingele, K. Szabo; Hungary: M. Szabo; Italy: C. Ferrarese,
G. Neri, E. Parati; The Netherlands: W. M. Mulleners; Poland:
J. Pniewski, K. Selmaj, A. Wajgt; Singapore: H. M . Chang,
N. V . Ramani; Spain: A. Arboix Damunt, E. Diez Tejedor,
O. Fernandez Fernandez, G. Izquierdo Ayuso, J. Roquer
Gonzalez; Switzerland: P. Lyrer, P. Michel; Taiwan:
K.-C. Chang; The United Kingdom: M. Dennis, K. Muir.
MRI project investigators by country
Australia: N. Ferris, S. Hudson, L. Masters, H. Prime, B.
Tress; Austria: F. A. Fellner, S. Ropele, D. Zur Nedden;
Belgium: T. Stadnik, L. Tshibanda; Brazil: L. Alberto
Moreira De Souza, A. C. M. Maia Junior, M. S. Nacif, A.
Sarmet Dos Santos; Canada: M. Heran, W. Hu, D. Mikulis;
France: F. De Broucker, J. Gabrillargues, J-P. Guichard, Y.
Narboux, C. Oppenheim, P. Wagner; Germany: A. Bor-
mann, O. Jansen, R. Kern, R. Klingebiel, G. Layer, K.
Wernecke; Hungary: E. Torok; Italy: E. Ciceri, M. Grim-
aldi, P. Ottaviano; The Netherlands: D. Venderink; Poland:
M. Konopka, K. Selmaj, J. Walecki; Singapore: W. E. H.
Lim, Y-Y. Sitoh; Spain: L. Ballenilla, C. Caparros-Escu-
dero, A. Ferna´ndez Prieto, E. Mundt, J. Perich; Switzer-
land: P. Maeder, E-W. Radue; Taiwan: Y-L. Kuo; The
United Kingdom: K. Muir, J. Wardlaw.
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